Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kang Ting
University of California Los Angeles, Department: Dentistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bone Biologics, Inc
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Professor Ting is a co-investigator and founder of the company.
Novel systemic PEGylated NELL-1 therapy for craniofacial osteoporosis
PUBLIC HEALTH RELEVANCE Osteoporosis is the most common metabolic bone disease, with an estimated biomedical and economic burden projected to reach $240 billion worldwide by 2040. New anabolic, anti-osteoclastic therapies for both general osteoporosis and associated craniofacial osteoporotic bone loss ? particularly in the alveolar and mandibular condylar bones ? are urgently needed. Our innovative solution utilizes PEGylated NELL-1, a pharmacokinetically enhanced bone-forming Wnt activator, as an entirely novel systemic therapy to simultaneously reverse general and craniofacial osteoporotic bone loss.
Filed on May 19, 2017.
Tell us what you know about Kang Ting's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Kang Ting”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Kang Ting | University of California Los Angeles | Conflict of Interest | Bone Biologics | Value cannot be readily determined |
| Kang Ting | University of California Los Angeles | Conflict of Interest | Bone Biologics Inc | Value cannot be readily determined |
| Kang Ting | University of California Los Angeles | Financial Disclosure | Bone Biologics Corp | |
| Kang Ting | University of California Los Angeles | Conflict of Interest | Bone Biologics | Value cannot be readily determined |
| Kang Ting | University of California Los Angeles | Conflict of Interest | Bone Biologics Inc | Value cannot be readily determined |
| Kang Ting | University of California Los Angeles | Conflict of Interest | Bone Biologics | Value cannot be readily determined |
| Kang Ting | University of California Los Angeles | Conflict of Interest | Bone Biologics | Value cannot be readily determined |
| Kang Ting | University of California Los Angeles | Conflict of Interest | Bone Biologics, Inc. | Value cannot be readily determined |
| Kang Ting | University of California Los Angeles | Conflict of Interest | Bone Biologics, Inc | $0 - $4,999 |
| Kang Ting | University of California Los Angeles | Conflict of Interest | Bone Biologics | $60,000 - $79,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.